Clinical trial
Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1…
NCT00043706 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00043706 |
|---|---|
| Title | Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis |
| Official title | A Phase 1/2 Double Blind, Placebo Controlled, Randomized, Dose Ranging, Repeat Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CAT-192 Human Anti-TGF-Beta1 Monoclonal Antibody in Patients With Early Stage Diffuse Systemic Sclerosis |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Collaborators | Cambridge Antibody Technology |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Systemic Sclerosis, Scleroderma |
| Intervention type | Drug |
| Interventions | Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody |
| Completion | Sep 1, 2003 |
| First posted | Aug 14, 2002 |
| Last update posted | Mar 5, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: